Selective advantage of HIV protease mutations associated with resistance to lopinavir

被引：0
|
作者：
Molla, A. [1 ]
Lu, L. [1 ]
King, M. [1 ]
Woods, R. [2 ]
Pilot-Matias, T. [1 ]
Lam, E. [3 ]
Whitcomb, J. [3 ]
Bernstein, B. [1 ]
Hanna, G. [1 ]
Kempf, D. [1 ]
机构：
[1] Global Pharmaceut Res & Dev, Abbott Pk, IL USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Monogram Biosci, San Francisco, CA USA
来源：
ANTIVIRAL THERAPY | 2007年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S85 / S85
页数：1
相关论文
共 50 条
  • [21] Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance
    de Mendoza, Carmen
    Garrido, Carolina
    Corral, Angelica
    Zahonero, Natalia
    Soriano, Vincent
    AIDS, 2008, 22 (02) : 311 - 313
  • [22] PATTERNS OF SPECIFIC MUTATIONS IN HIV-1 PROTEASE THAT CONFER RESISTANCE TO A PANEL OF PROTEASE INHIBITORS
    MO, HM
    MARKOWITZ, M
    HO, DM
    DIAMOND, A
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, : 195 - 195
  • [23] Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy
    Jiménez, JL
    Resino, S
    Martinez-Colom, A
    Bellón, JM
    Muñoz-Fernández, MA
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (06) : 1081 - 1086
  • [24] Synthesis of HIV protease inhibitor ABT-378 (Lopinavir)
    Stoner, EJ
    Cooper, AJ
    Dickman, DA
    Kolaczkowski, L
    Lallaman, JE
    Liu, JH
    Oliver-Shaffer, PA
    Patel, KM
    Paterson, JB
    Plata, DJ
    Riley, DA
    Sham, HL
    Stengel, PJ
    Tien, JHJ
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2000, 4 (04) : 264 - 269
  • [25] Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment
    Barragan, Patricia
    Podzamczer, Daniel
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (13) : 2363 - 2375
  • [26] TEMPORAL DYNAMIC OF MUTATIONS ASSOCIATED WITH HCV PROTEASE INHIBITORS RESISTANCE IN NATURAL STRAINS OF HIV/HCV COINFECTED INDIVIDUALS
    Messina, E.
    Bagaglio, S.
    Merli, M.
    Porrino, L.
    Pignataro, A. R.
    Boeri, E.
    Hasson, H.
    Lazzarin, A.
    Carbone, A.
    Morsica, G.
    Uberti-Foppa, C.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S474 - S474
  • [27] Temporal characterization of frequency of drug-resistance associated mutations in the HIV-1 protease and reverse transcriptase
    Ceccherini-Silberstein, F
    Santoro, M
    Svicher, V
    Gori, C
    Zaccarelli, M
    Forbici, F
    d'Arrigo, R
    Trotta, MP
    Bellocchi, MC
    Visco-Comandini, U
    Giannella, S
    Bertoli, A
    Antinori, A
    Perno, CF
    ANTIVIRAL THERAPY, 2004, 9 (04) : U84 - U84
  • [28] Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients
    Hasson, H
    Gianotti, N
    Danise, A
    Seminari, E
    Boeri, E
    Nozza, S
    Castagna, A
    Lazzarin, A
    AIDS, 2004, 18 (01) : 123 - 127
  • [29] Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance
    de Mendoza, C
    Valer, L
    Bacheler, L
    Pattery, T
    Corral, A
    Soriano, V
    AIDS, 2006, 20 (07) : 1071 - 1073
  • [30] Mutations in the protease gene and factors associated with virological failure to lopinavir/ritonavir-containing regimens in clinical samples
    Santos, J. R.
    Llibre, J. M.
    Domingo, P.
    Arkaitz, A. Imaz
    Samuel, S. Vanegas
    Clotet, B.
    ANTIVIRAL THERAPY, 2011, 16 : A78 - A78
12345